Sensorium Therapeutics Announces SNTX-2643 Phase 1a Data to Be Presented at Psych Congress 2026

Phase 1SNTX-2643Positive

AI Analysis

Summary

Sensorium Therapeutics announced Phase 1a clinical data for SNTX-2643, a small-molecule CNS therapeutic, to be presented at Psych Congress 2026. The announcement provides no outcome details or efficacy results.

Clinical Trial Data

Phase

Importance:4/10

Sentiment:

0.50

Phase 1a dataCNSpsychiatryconference presentationsmall-molecule

Read the original article

Published by PR Newswire Biotech on August 19, 2026 1:41 PM

Read Original